Penn Capital Management Company LLC Purchases New Position in CONMED Corporation $CNMD

Posted by on May 27th, 2026

Penn Capital Management Company LLC acquired a new stake in CONMED Corporation (NYSE:CNMD – Free Report) in the fourth quarter, HoldingsChannel reports. The institutional investor acquired 51,493 shares of the company’s stock, valued at approximately $2,091,000.

Other large investors have also modified their holdings of the company. Kelleher Financial Advisors acquired a new stake in CONMED in the 3rd quarter valued at approximately $28,000. Quarry LP boosted its stake in CONMED by 244.8% in the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after purchasing an additional 617 shares during the period. Huntington National Bank boosted its stake in CONMED by 111.8% in the 3rd quarter. Huntington National Bank now owns 883 shares of the company’s stock worth $42,000 after purchasing an additional 466 shares during the period. State of Wyoming acquired a new stake in shares of CONMED during the 3rd quarter valued at $52,000. Finally, Cullen Frost Bankers Inc. bought a new position in shares of CONMED during the 4th quarter valued at $54,000.

CONMED Price Performance

NYSE:CNMD opened at $36.06 on Wednesday. CONMED Corporation has a 52 week low of $33.21 and a 52 week high of $60.35. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of 20.37, a P/E/G ratio of 1.67 and a beta of 0.94. The firm’s 50-day simple moving average is $36.76 and its 200 day simple moving average is $40.00. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.29.

CONMED (NYSE:CNMD – Get Free Report) last released its earnings results on Wednesday, April 29th. The company reported $0.89 EPS for the quarter, beating the consensus estimate of $0.82 by $0.07. CONMED had a net margin of 4.00% and a return on equity of 13.84%. The firm had revenue of $317.05 million for the quarter, compared to analyst estimates of $310.64 million. During the same period last year, the firm earned $0.95 EPS. The business’s quarterly revenue was down 1.3% compared to the same quarter last year. As a group, sell-side analysts predict that CONMED Corporation will post 4.38 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Wells Fargo & Company dropped their target price on shares of CONMED from $42.00 to $39.00 and set an “equal weight” rating on the stock in a report on Friday, May 1st. Needham & Company LLC reaffirmed a “hold” rating on shares of CONMED in a research note on Thursday, January 29th. Wall Street Zen downgraded shares of CONMED from a “strong-buy” rating to a “buy” rating in a research note on Saturday, May 2nd. Bank of America lowered their target price on shares of CONMED from $52.00 to $40.00 and set a “neutral” rating for the company in a research note on Monday, May 18th. Finally, Piper Sandler cut shares of CONMED from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $55.00 to $39.00 in a report on Tuesday, March 17th. Six investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Reduce” and an average price target of $43.80.

Check Out Our Latest Stock Analysis on CONMED

CONMED Company Profile

(Free Report)

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.

Read More

Want to see what other hedge funds are holding CNMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CONMED Corporation (NYSE:CNMD – Free Report).

Institutional Ownership by Quarter for CONMED (NYSE:CNMD)

Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.